Each card leads with priority, lifecycle, applicability, and deadline, then the detail.
P1
CARRYOVER
Operationally relevant
Settled
- What changed
DOJ announced September 18, 2026 agreements with NYU Langone Hospitals and the University of Pittsburgh Medical Center resolving investigations of potential federal violations associated with gender-affirming care for minors. According to the announcement, the institutions will cease providing puberty blockers, cross-sex hormones and surgical procedures to minors. NYU agreed to pay $8.5 million and UPMC $950,000, a combined $9.45 million. These are the institutions' reported resolution commitments; the announcement does not establish that every other provider is subject to the same terms.
The release connects the investigations to potential Food, Drug, and Cosmetic Act, False Claims Act and other federal health care-law violations, including allegedly false diagnosis codes used for reimbursement. DOJ credited both institutions for cooperation, including ongoing cooperation concerning other entities. It expressly states that the resolved claims are allegations only, no liability determination was made and NYU and UPMC denied all allegations. Those distinctions matter when using the event to review billing support or service governance: a settlement is different from an adjudication of the allegations. Counsel should assess the executed terms and applicable state and federal obligations before drawing operational conclusions for a particular organization.
- Why it matters
- The resolutions put diagnosis support, reimbursement representations and service-line oversight in the same risk review, while retaining entity-specific and disputed-claim limits.
- Response type
- Assess
- Confidence
- High
- Who this affects
- Health systems, Provider networks
- Jurisdiction
- Federal, New York, Pennsylvania
- Agencies
- U.S. Department of Justice, HHS Office of Inspector General, Food and Drug Administration Office of Criminal Investigations
- Entities
- NYU Langone Hospitals, University of Pittsburgh Medical Center
- Action type
- Resolution agreement
- Event date
- Sep 18, 2026
- Alleged conduct
- Potential violations involving pediatric services and allegedly false diagnosis codes used to obtain federal program and private-insurer payment. The institutions denied the allegations, and there was no determination of liability.
- Resolution
- NYU agreed to pay $8.5 million, UPMC agreed to pay $950,000, and both agreed to cease the specified services for minors.
- First seen
- Sep 20, 2026
- Last materially changed
- Sep 20, 2026
- Why it is still here
- Retained for the case-informed control review described in the recommended action, based on the dated resolution agreement matter and its operational mechanism.
What to do nextHave counsel review relevant agreements and current legal duties. Validate diagnosis and claim support, pharmacy and consent controls, and document oversight of any proposed service-line decision.
- Service-line decisions require coordinated legal, coding, pharmacy, and executive oversight.
- Diagnosis codes used to support payment need contemporaneous clinical support.
- Cooperation can materially shape a resolution even when allegations are denied.
Permalink: #nyu-upmc-pediatric-care-federal-resolutions · Development ID GC-2026-0103
P1
CARRYOVER
Operationally relevant
Settled
- What changed
A September 2026 settlement agreement provides for Abbott to pay $384,999,040.12 plus interest in connection with disputed claims involving powdered infant formula and nutritional products. The government contends that, from January 2018 through December 2022, Abbott failed to comply with federal and state manufacturing obligations at its Sturgis, Michigan and Casa Grande, Arizona facilities and misrepresented compliance to WIC and Medicaid programs. The agreement is a compromise, not an admission of facts or liability. Abbott denies the allegations, and the United States does not concede that its claims lack merit. DOJ announced the resolution September 14; this tracked event date is an announcement date, not proof of the agreement’s last-signature effective date.
The payment provisions separate $348,700,868 for the United States, $35,491,288.40 for participating Medicaid states and $806,883.72 for Massachusetts's supplemental WIC appropriation, with specified interest terms. The agreement conditions relevant releases on receipt of payment and reserves categories including criminal liability, certain administrative enforcement, individual liability and conduct outside the defined covered conduct. It also addresses unallowable settlement-related costs previously claimed from federal programs. Its effective date is the date of the last signature, rather than an assumption that every payment or release occurred when one government representative signed. These terms connect manufacturing compliance representations to government-program claims while keeping the settlement's scope and unresolved rights intact.
- Why it matters
- Government-program suppliers need traceable support for product-quality and eligibility representations, including when manufacturing deviations may undermine continued claims or rebates.
- Response type
- Assess
- Confidence
- High
- Who this affects
- Health systems, Provider networks
- Jurisdiction
- Federal, California
- Agencies
- U.S. Department of Justice, U.S. Department of Agriculture, HHS Office of Inspector General, State Medicaid programs
- Entities
- Abbott Laboratories
- Action type
- Settlement
- Event date
- Sep 14, 2026
- Alleged conduct
- Alleged failure to manufacture covered formula and nutritional products in compliance with requirements and alleged misrepresentations to WIC and Medicaid programs. Abbott denied the allegations.
- Resolution
- Agreement to pay $384,999,040.12 plus interest, with federal, Medicaid-state and Massachusetts allocations. Specified releases depend on payment and reserved claims remain; completed payment and exact last-signature effective date are not established.
- First seen
- Sep 20, 2026
- Last materially changed
- Sep 20, 2026
- Why it is still here
- Retained for the case-informed control review described in the recommended action, based on the dated settlement matter and its operational mechanism.
What to do nextMap program and contract quality representations to manufacturing evidence and escalation records. Review continued submissions after deviations, settlement-cost allowability where applicable, and the exact scope of any release with counsel.
- Product-quality deviations can create payment-integrity exposure.
- Program eligibility representations need continuing support.
- Unallowable settlement costs must be separated from government-program claims and cost reporting.
Permalink: #abbott-infant-formula-fca-settlement · Development ID GC-2026-0105
P1
CARRYOVER
Operationally relevant
Final
- What changed
OIG's September 2026 hospital audits reported different scales of overpayment. At Methodist, 27 of 100 reviewed claims did not fully meet billing requirements, producing $256,926 in sampled net overpayments. OIG estimated at least $12.4 million in net overpayments across selected types of services within $62 million in Medicare payments. At McLeod Regional Medical Center, 17 of 115 reviewed claims produced $38,676 in net overpayments. Both summaries identify January 2020 through December 2021 as the audit period. Methodist's estimate should therefore be distinguished from its sample error amount, and neither audit is a finding about every hospital claim.
OIG attributed the errors primarily to failures to follow policies and procedures in the selected risk areas and recommended refunds, consideration of later-period internal audits and additional training. Methodist did not concur with the refund and internal-audit recommendations but expressed willingness to provide education. McLeod agreed with most findings, did not state concurrence or nonconcurrence with the recommendations, and said it would refund agreed overpayments and described corrective steps. Those responses are not equivalent admissions. The reports are dated September 17 for Methodist and September 16 for McLeod.
- Why it matters
- The audits support testing actual claim controls and distinguishing sample findings, estimates, recommendations and provider responses before quantifying an organization's own exposure.
- Response type
- Validate
- Confidence
- High
- Who this affects
- Health systems, Provider networks
- Jurisdiction
- Federal
- Agencies
- HHS Office of Inspector General
- Entities
- Methodist Hospital, McLeod Regional Medical Center
- Action type
- Audit
- Event date
- Sep 17, 2026
- Alleged conduct
- OIG identified sampled Medicare claim errors and estimated or calculated overpayments.
- Resolution
- OIG issued audit findings and recommendations for repayment and strengthened controls.
- First seen
- Sep 20, 2026
- Last materially changed
- Sep 20, 2026
- Why it is still here
- Retained for the case-informed control review described in the recommended action, based on the dated audit matter and its operational mechanism.
What to do nextReview the full reports' risk categories before selecting claims for audit. Quantify any identified overpayment, obtain counsel's repayment-timing analysis where required and document control changes and follow-up.
- Use targeted claim audits to identify systemic payment risk.
- Escalate credible overpayment findings promptly.
- Document coding, billing, and repayment corrective actions.
Permalink: #oig-hospital-compliance-audits · Development ID GC-2026-0121
P1
NEW
Operationally relevant
Settled
- What changed
The September 23, 2026 RegalCare announcement concerns a $1 million settlement with RegalCare entities, Eliyahu Mirlis and Hector Caraballo. The signed agreement provides $880,000 for the United States and $120,000 for Massachusetts, plus specified interest, and includes admitted facts about Medicare and MassHealth billing. Its Medicare admissions cover April 2018 through September 2019, while its Medicaid admissions cover April 2018 through September 2023; the broader government contentions are separately stated. Some Ultra High RUG claims lacked support from individual patient need and should have been billed lower. The historical RUG model described in the agreement should not be mistaken for the current Medicare payment methodology.
The agreement identifies Caraballo as a licensed practical nurse and reimbursement executive. It states that accurate MDS modifications were permitted regardless of professional licensure, while applicable assessments required registered-nurse certification. Caraballo made changes without visibly assessing or speaking to patients; some changes occurred without clinician discussions, others after clinician discussions and/or medical-record review, and an RN signed the completed MDS afterward at his request. It also records some billing before assessments were fully finalized and describes MMQ reviews that increased MassHealth reimbursement. The lesson is not that an executive could never modify an assessment, but that patient support, certification and billing readiness must be verified. These specific admissions should remain distinct from all broader disputed government allegations.
- Why it matters
- Assessment-change controls need patient-specific support, accurate RN certification and billing readiness, without imposing an unsupported clinician-only editing rule.
- Response type
- Assess
- Confidence
- High
- Who this affects
- Health systems, Provider networks
- Jurisdiction
- Federal
- Agencies
- U.S. Attorney Office, District of Massachusetts
- Entities
- RegalCare Management Group LLC and executives
- Action type
- Settlement
- Event date
- Sep 23, 2026
- Alleged conduct
- Government contentions concern unnecessary or overstated SNF services. Specific admitted facts include some unsupported Ultra High RUG claims, qualified MDS changes by an LPN executive with subsequent RN certification, some pre-finalization billing and MMQ reviews increasing reimbursement; broader contentions remain distinct.
- Resolution
- The entities and executives agreed to $1 million plus interest and specified factual admissions. The agreement conditions specified government monetary releases and dismissal on receipt of payment and preserves reserved claims; the announcement is not proof of completed payment or universal release.
What to do nextReview assessment change history, supporting records, RN certification and claim-release timing. Test patient-specific support for reimbursement levels and distinguish historical RUG/MMQ mechanisms from current payment rules.
- Verify patient-specific support for assessment changes and reimbursement levels.
- Preserve applicable RN certification and complete assessment evidence before billing.
- Accurate MDS editing is distinct from assessment certification and is not categorically limited by professional licensure under the cited agreement.
Permalink: #regalcare-snf-therapy-overbilling-settlement · Development ID GC-2026-0129
P2
CARRYOVER
Operationally relevant
Settled
- What changed
DEA’s August 28 announcement describes a $50 million settlement resolving allegations that Walmart pharmacies filled thousands of invalid prescriptions for opioids and other controlled substances. The government’s complaint was filed December 22, 2020 and amended in 2022; the alleged conduct began June 26, 2013. According to the release, pharmacists reported suspected pill-mill prescribers through thousands of refusal-to-fill forms, while compliance-team members and pharmacists allegedly filled invalid prescriptions despite that information. The warning signs included dangerous drug combinations, repeated high-dose prescriptions and recurring early-fill requests. These are the government’s allegations in the resolved case, not an adjudicated finding of liability.
In addition to the monetary resolution, Walmart entered a memorandum of agreement with DEA addressing future dispensing controls. The release describes a hotline for employees and patients, proactive monitoring of pharmacy dispensing patterns, and a process for evaluating prescribers suspected of illegal prescribing. Those commitments connect information gathered at individual pharmacies with corporate review and action. The settlement therefore illustrates both frontline dispensing judgment and what an organization does with warning reports it already receives. The monetary and monitoring commitments resolve allegations; the announcement does not independently document completed payment.
- Why it matters
- Collecting refusal-to-fill reports is only one part of a dispensing-control system. Pharmacy compliance teams need a process to review patterns, escalate concerns and document decisions while preserving legitimate patient access.
- Response type
- Assess
- Confidence
- High
- Who this affects
- Health systems
- Jurisdiction
- Federal
- Agencies
- U.S. Department of Justice, Civil Division, Drug Enforcement Administration
- Entities
- Walmart Inc.
- Action type
- Settlement
- Event date
- Aug 28, 2026
- Alleged conduct
- Alleged unlawful filling of controlled-substance prescriptions despite pharmacist reports, suspected pill-mill prescribers and prescription red flags; the complaint describes conduct beginning June 26, 2013.
- Resolution
- $50 million settlement and DEA memorandum of agreement announced August 28, 2026. Agreement includes an employee/patient hotline, proactive dispensing monitoring and suspected-prescriber evaluation. Claims remain allegations with no liability determination; completed payment not separately established.
- First seen
- Aug 30, 2026
- Last materially changed
- Aug 30, 2026
- Why it is still here
- Retained for review of dispensing-warning reports, prescriber escalation and reporting routes described in the August 28 resolution.
What to do nextPharmacy leaders should trace a sample of warning reports from receipt through review and documented action, test prescriber-pattern escalation and review employee/patient reporting routes. These are operational recommendations informed by the agreement, not a claim that every pharmacy has Walmart’s negotiated obligations.
- Review and act on refusal-to-fill reports rather than treating collection as completion.
- Link pharmacy dispensing patterns with prescriber-review escalation.
- Provide reporting routes for employees and patients and retain evidence of follow-up.
Permalink: #walmart-controlled-substances-dispensing-settlement · Development ID GC-2026-0006
P2
CARRYOVER
Operationally relevant
Final
- What changed
DOJ announced September 4, 2026 sentences of 33 months for Kenneth Charles Kessler III and 24 months for Michael Andrew Gomez. Both had pleaded guilty in May to conspiracy to commit health care fraud. They owned and operated seven Florida durable medical equipment companies that billed Medicare for medically unnecessary orthotic braces, including braces beneficiaries neither needed nor requested. The $34.8 million figure describes the fraudulent billing scheme, rather than a statement that either individual received that amount personally.
According to the court-document account in the announcement, the operators paid kickbacks and bribes for fraudulent signed physician orders and used those orders to ship braces nationwide. They shifted billing among their companies to evade Medicare payment suspensions. DOJ reported that Kessler profited more than $1.4 million and Gomez more than $2.3 million. The related-company structure and order-generation process are distinct elements of the admitted scheme: checking only a supplier's current billing identity would not address the mechanism DOJ described. These are facts of the resolved criminal case, not a new rule changing DME coverage requirements.
- Why it matters
- DME fraud review needs to connect ownership, order sources and beneficiary receipt across related supplier identities, especially after payment suspensions.
- Response type
- Assess
- Confidence
- High
- Who this affects
- Health systems, Provider networks
- Jurisdiction
- Federal
- Agencies
- DOJ
- Entities
- Kenneth Charles Kessler III, Michael Andrew Gomez
- Action type
- Criminal resolution
- Event date
- Sep 4, 2026
- Alleged conduct
- Medicare billing for unnecessary braces using kickbacks and fraudulent orders; billing shifted between supplier entities.
- Resolution
- Prison sentences announced following guilty pleas; the $34.8 million figure is scheme billing, not the amount of a fine.
- First seen
- Sep 6, 2026
- Last materially changed
- Sep 6, 2026
- Why it is still here
- Retained for the organizational control review described in the recommended action, informed by the dated criminal resolution matter and its documented operational mechanism.
What to do nextReview DME supplier relationships, paid referral arrangements, individualized order authenticity and beneficiary receipt. Investigate billing shifts among related entities when suspension or other fraud alerts arise.
- Validate referrals and orders independently.
- Monitor related supplier entities and payment suspension evasion.
Permalink: #florida-dme-brace-fraud-sentences · Development ID GC-2026-0027
P2
CARRYOVER
Operationally relevant
Final
- What changed
Rebecca Fadanelli, owner of Skin Beaute Med Spa in Massachusetts, was sentenced September 2, 2026 to 46 months in prison and two years of supervised release, DOJ announced September 4. The court also ordered restitution and forfeiture, each $1,001,562. She had pleaded guilty in April to unlawful importation and selling or dispensing counterfeit drugs and devices.
DOJ reports more than 2,700 counterfeit botulinum-toxin and filler procedures affecting over 900 paying clients during roughly March 2021–June 2024. Fadanelli was an aesthetician without authority to administer the injections and falsely claimed to be a nurse. Products were imported from China and Brazil, and she changed delivery arrangements after seizures. Manufacturers identified seized products as counterfeit. Clients suffered serious adverse effects, including infections, facial or eye problems and hospitalizations. The case connects independent license checks, product provenance and response to patient complaints; a familiar brand label or claimed nursing credential did not establish legitimacy.
- Why it matters
- The source documents patient harm alongside counterfeit supply and false credentials, requiring controls that connect procurement, clinical authorization and adverse-event escalation.
- Response type
- Assess
- Confidence
- High
- Who this affects
- Health systems, Provider networks
- Jurisdiction
- Federal
- Agencies
- DOJ
- Entities
- Rebecca Fadanelli, Skin Beaute Med Spa
- Action type
- Criminal resolution
- Event date
- Sep 2, 2026
- Alleged conduct
- Counterfeit botulinum toxin and dermal fillers were administered while the owner falsely claimed to be a nurse.
- Resolution
- September 2, 2026 sentence: 46 months imprisonment, two years supervised release, and separate restitution and forfeiture orders each $1,001,562, after guilty plea.
- First seen
- Sep 6, 2026
- Last materially changed
- Sep 6, 2026
- Why it is still here
- Retained for the organizational control review described in the recommended action, informed by the dated criminal resolution matter and its documented operational mechanism.
What to do nextVerify injector licenses through the issuing board and trace products through authorized sources. Quarantine suspect stock and promptly escalate adverse-event reports.
- Verify licensure with the issuing board.
- Trace injectable products to authorized sources and preserve lot records.
Permalink: #skin-beaute-counterfeit-injection-sentence · Development ID GC-2026-0040
P2
CARRYOVER
Operationally relevant
Settled
- What changed
DOJ's September 2, 2026 release announced that Heuser Health, a Louisville provider of at-home wound care, agreed to pay $2,646,186.72 to resolve False Claims Act allegations involving Medicare and TRICARE skin-substitute claims. The settlement forms part of the department's broader Operation Skin Scam initiative. DOJ expressly states that the claims are allegations only and there was no determination of liability. The release establishes an agreement to pay, rather than independent proof of completed payment.
Heuser used advanced bioengineered or tissue-derived skin substitutes to treat chronic and acute wounds. According to DOJ, the federal rules applicable to these claims required billing based on actual invoice price, but the company allegedly submitted or caused claims using invoice amounts higher than its true purchase prices. The alleged mismatch concerned acquisition cost and reimbursement, rather than a finding that every wound-care service was unnecessary. Its operational relevance is to claims that actually use invoice-based reimbursement; the case does not establish one payment methodology for all products, payers or care settings.
- Why it matters
- Invoice-supported claims must reconcile to actual acquisition costs under the applicable payment rule, including relevant credits and discounts.
- Response type
- Assess
- Confidence
- High
- Who this affects
- Health systems, Provider networks
- Jurisdiction
- Federal
- Agencies
- DOJ
- Entities
- Heuser Health
- Action type
- Settlement
- Event date
- Sep 2, 2026
- Alleged conduct
- Claims allegedly used invoice amounts above the true purchase price.
- Resolution
- Agreement to pay $2,646,186.72 to resolve civil False Claims Act allegations; no determination of liability or proof of completed payment in the release.
- First seen
- Sep 6, 2026
- Last materially changed
- Sep 6, 2026
- Why it is still here
- Retained for the organizational control review described in the recommended action, informed by the dated settlement matter and its documented operational mechanism.
What to do nextReconcile applicable skin-substitute claims to purchase records and actual costs, review credits or discounts, and document the payer rule used for the claim.
- Reconcile invoice-supported claims to actual acquisition costs.
- Review credits and discounts before finalizing claims.
Permalink: #heuser-health-skin-substitute-invoice-settlement · Development ID GC-2026-0041
P2
CARRYOVER
Operationally relevant
Pending litigation
- What changed
DOJ's September 2026 announcement describes a False Claims Act complaint against former Capstone Diagnostics executives and associated entities involving approximately $13.7 million in Medicare payments from 2019 through 2021. The government alleges two schemes: genetic testing at church-sponsored health fairs and religious conferences without physician requests, and medically unnecessary respiratory panels added to COVID-19 testing for senior-living communities. DOJ intervened September 4 in the whistleblower case brought by a former laboratory manager. The civil allegations remain unproven; the announcement does not report a judgment against these defendants.
The alleged order-generation methods included using physicians' identities and copied signatures without permission, community-wide or chain-wide standing orders, standardized diagnosis codes, sales personnel entering orders and remuneration tied to test volume. DOJ separately identified settlements with Capstone and its owner and with its billing company; those resolutions do not adjudicate the pending defendants' liability. The release also states that criminal charges against one former executive were pending. An operational review should therefore focus on the identified control patterns without treating either the civil complaint or indictment as a conviction: individualized clinical authorization, valid signatures, medical necessity and separation of sales activity from ordering.
- Why it matters
- The complaint links multiple laboratory safeguards that can fail together, especially when standardized ordering and marketer incentives replace patient-specific clinical support.
- Response type
- Assess
- Confidence
- High
- Who this affects
- Health systems, Provider networks
- Jurisdiction
- Federal, Georgia
- Agencies
- U.S. Department of Justice, HHS Office of Inspector General, Federal Bureau of Investigation
- Entities
- Former Capstone Diagnostics executives and associated entities
- Action type
- Civil complaint
- Event date
- Sep 17, 2026
- Alleged conduct
- Alleged medically unnecessary genetic and respiratory panel testing generated through mass events, copied signatures, standing orders, standardized diagnoses, sales ordering, and kickbacks.
- Resolution
- Complaint filed. Liability has not been determined.
- First seen
- Sep 20, 2026
- Last materially changed
- Sep 20, 2026
- Why it is still here
- Retained for the case-informed control review described in the recommended action, based on the dated civil complaint matter and its operational mechanism.
What to do nextSample genetic and respiratory claims for treating-provider authorization, signature validity, patient-specific diagnoses and necessity. Review standing orders, sales access and marketer compensation, escalating copied-signature or volume-linked patterns.
- Laboratory tests need individualized treating-provider orders.
- Sales personnel should not create clinical orders.
- Standing orders and copied signatures require focused monitoring.
- Marketer compensation must not reward federally reimbursed test volume.
Permalink: #capstone-laboratory-medicare-fca-complaint · Development ID GC-2026-0104
P2
CARRYOVER
Operationally relevant
Settled
- What changed
DOJ announced September 17, 2026 that Remedi SeniorCare Holding Corporation agreed to pay more than $5.3 million to resolve False Claims Act allegations involving drugs dispensed without valid prescriptions. The government alleged false Medicare and Medicaid claims from January 1, 2015 through March 31, 2021 for drugs supplied to assisted-living residents in various states. The release says the settlement reflects Remedi's ability to pay and will be paid over time. It does not establish that the full amount had already been collected by this edition’s coverage cutoff.
The resolution includes claims raised by two former employees under the False Claims Act's whistleblower provisions, with a share of payments to be paid to them over time. The announcement expressly says the settled claims are allegations only and there has been no determination of liability. The case therefore supports a focused review of prescription-validity and billing safeguards rather than a conclusion that every resident's prescription was invalid or that the company was convicted. Facilities and pharmacy partners should distinguish the resident's need for continued medication from the separate requirement to retain a valid, timely prescribing basis for dispensing and reimbursement.
- Why it matters
- Long-term care medication workflows need reliable prescriber-order evidence and claim controls when prescriptions are missing, expired or otherwise invalid.
- Response type
- Assess
- Confidence
- High
- Who this affects
- Health systems, Provider networks
- Jurisdiction
- Federal, Maryland
- Agencies
- HHS Office of Inspector General
- Entities
- Remedi SeniorCare
- Action type
- Settlement
- Event date
- Sep 17, 2026
- Alleged conduct
- Billing federal healthcare programs for drugs allegedly dispensed without valid prescriptions.
- Resolution
- Agreement to pay more than $5.3 million based on ability to pay and in installments over time, resolving disputed civil False Claims Act allegations; no liability determination or completed collection established.
- First seen
- Sep 20, 2026
- Last materially changed
- Sep 20, 2026
- Why it is still here
- Retained for the case-informed control review described in the recommended action, based on the dated settlement matter and its operational mechanism.
What to do nextAudit prescription-validity checks, order retention, emergency and refill workflows, and claim edits. Resolve missing or expired orders with clinical and pharmacy teams without inferring that operational recommendations are new settlement-wide rules.
- Validate prescription authority before dispensing and billing.
- Retain accessible prescriber-order evidence.
- Use claim edits to stop billing when required order data is missing.
Permalink: #remedi-invalid-prescriptions-settlement · Development ID GC-2026-0122
P2
NEW
Operationally relevant
Settled
- What changed
DOJ announced September 21, 2026 that Crown Medical Solutions LLC and owners Michelle and Philanzo King agreed to pay $825,000 to resolve False Claims Act allegations. Crown supplied durable medical equipment, including knee and back braces and heel stabilizers. The government alleged that, from November 2017 through April 2019, the company and owners billed Medicare for equipment that was not medically necessary and/or properly prescribed. The release expressly says the claims are allegations only and there was no determination of liability.
The settlement amount reflects the defendants' ability to pay, so it should not be equated with a judicial calculation of all alleged loss. The resolution includes a whistleblower action, with the relator to receive approximately $123,750. The reported conduct centers on the medical necessity and physician-prescribing basis for DME claims. It does not establish that the equipment was never delivered, that every Crown claim was invalid or that a court convicted the owners. Supplier review should therefore compare each claim's order and clinical support with the actual case scope, with the clinical and order evidence relevant to the DME supplied.
- Why it matters
- DME claim integrity depends on valid prescribing and patient-specific necessity; ability-to-pay settlements and unresolved allegations should be interpreted separately.
- Response type
- Assess
- Confidence
- High
- Who this affects
- Health systems, Provider networks
- Jurisdiction
- Federal
- Agencies
- U.S. Department of Justice
- Entities
- Crown Medical Solutions LLC and its owners
- Action type
- Settlement
- Event date
- Sep 21, 2026
- Alleged conduct
- Alleged Medicare billing for durable medical equipment that was not medically necessary or was not properly prescribed.
- Resolution
- Crown Medical Solutions and its owners agreed to pay $825,000 to resolve False Claims Act allegations. The claims resolved are allegations only, with no determination of liability.
What to do nextSample DME claims for physician prescribing and medical-necessity support. Review ownership oversight and escalation of unsupported orders, and have counsel assess case relevance without treating allegations as adjudicated facts.
- Verify DME medical necessity and valid physician prescribing before billing.
- Test supplier and owner oversight of order-support exceptions.
- Distinguish disputed allegations and ability-to-pay settlement amounts from adjudicated loss.
Permalink: #crown-medical-dme-billing-settlement · Development ID GC-2026-0130
P2
NEW
Operationally relevant
Final
- What changed
California's Attorney General announced September 21, 2026 that Maki Martinez-Gruninger pleaded guilty to one felony count of Medi-Cal false claims and would serve two years in state prison. The investigation identified $413,643.30 in false IHSS and respite-care claims. The case involved a disabled family member whose actual caregiver reported discovering the scheme. This is a criminal resolution, rather than an unresolved civil allegation or an administrative audit.
According to the release, the complainant discovered in December 2019 that Martinez-Gruninger had secretly applied in November 2007 to act as the family member's IHSS provider. The resulting false claims continued for more than a decade. The Attorney General reports that investigators found intentional taking of Medi-Cal funds and presentation of false claims. Those details point to service-provider identity, enrollment and verification of who actually delivered care. Family relationships should not substitute for independent confirmation of provider status and delivered services.
- Why it matters
- Long-running personal-care fraud can depend on inaccurate provider enrollment and weak confirmation of the actual caregiver, even within a family.
- Response type
- Assess
- Confidence
- High
- Who this affects
- Health systems, Provider networks
- Jurisdiction
- California
- Agencies
- California Department of Justice
- Entities
- Maki Martinez-Gruninger
- Action type
- Criminal resolution
- Event date
- Sep 21, 2026
- Alleged conduct
- False IHSS and respite-care claims totaling $413,643.30 were submitted over more than a decade using a disabled family member services.
- Resolution
- The defendant pleaded guilty to one felony count of Medi-Cal false claims and received a two-year state-prison sentence.
What to do nextReview IHSS or respite provider enrollment, beneficiary/caregiver confirmation and service documentation. Escalate conflicting caregiver identities or claims inconsistent with actual care and preserve an independent reporting route.
- Confirm provider enrollment and who actually delivers authorized personal-care services.
- Reconcile claims with beneficiary and caregiver evidence.
- Investigate conflicting caregiver identities and maintain independent complaint channels.
Permalink: #california-medi-cal-fraud-guilty-plea · Development ID GC-2026-0131
P2
NEW
Operationally relevant
Announced
- What changed
CDPH records identify fourteen citations issued September 21–25, 2026 across thirteen facilities, with two at Intercommunity Care Center. The recorded initial assessment amounts total $115,500. They include $60,000 for one Intercommunity patient-care citation, $25,000 for Sunnyside Nursing Center and $3,500 for Coral Cove Post Acute’s Willful Material Falsification citation. These are initial amounts attached to dated issuance records, not collections or proof of final appeal outcomes. A later export does not establish the historical Open/Closed status, balances or timing of any increases.
Six Abuse/Facility Not Self Reported rows concern Lindsay Gardens, Solaria Care–Auburn, Southland, Capital Post Acute, Intercommunity and Sharon Care Center. The facilities include skilled nursing, pediatric day health/respite and intermediate care for people with developmental disabilities, so this is not fourteen nursing-home cases. Violation dates predate the issue dates. Categories and legal references support targeted review but do not supply complete incident narratives, resident outcomes or corrective plans; those require the underlying citations.
- Why it matters
- Initial assessments and dated categories identify care, reporting and record-integrity review priorities across different facility types without proving detailed incidents or historical final status.
- Response type
- Assess
- Confidence
- High
- Who this affects
- Health systems, Provider networks
- Jurisdiction
- California
- Agencies
- CDPH
- Entities
- Creekside Healthcare Center, Lindsay Gardens Nursing & Rehabilitation, Solaria Care - Auburn, SOUTHLAND, Fairbanks House, Capital Post Acute, INTERCOMMUNITY CARE CENTER, SHARON CARE CENTER, Northvine Postacute Care, Sunnyside Nursing Center, Palos Verdes Health Care Center, Coral Cove Post Acute, Los Feliz Healthcare & Wellness Centre, LP
- Action type
- Civil monetary penalty
- Event date
- Sep 25, 2026
- Alleged conduct
- Export categories include patient care, abuse not self-reported and willful material falsification. Full citation narratives were not retrieved.
- Resolution
- Fourteen citations issued September 21–25 across thirteen facilities, initial amounts totaling $115,500. Historical disposition, collection, final amounts, appeal outcomes and timing of later adjustments are not established.
What to do nextObtain the individual citations, track appeal status separately from amounts assessed, and review patient-care escalation, required reporting and record accuracy at the relevant facility types.
- Verify timely abuse reporting and patient-care escalation.
- Maintain accurate facility records and obtain complete citation documents.
Permalink: #cdph-september-20-26-nursing-facility-citations · Development ID GC-2026-0138
P3
CARRYOVER
Operationally relevant
Effective
- What changed
FDA's final order, applicable August 31, 2026, permanently debars Rahim Shafa from providing services in any capacity to a person with an approved or pending drug product application and separately bars him for 20 years from importing or offering any drug for import. FDA denied his hearing request because it did not raise a genuine and substantial factual issue. The order rests on federal felony convictions for three unlawful-importation counts and one receiving-and-delivering-misbranded-drug count. These are FDA drug-regulation debarments, distinct from exclusion from federal healthcare programs.
The notice describes unapproved disulfiram and naltrexone products imported under false shipping descriptions and administered to patients. FDA treated the services bar as mandatory and imposed four consecutive five-year periods for the import bar after considering statutory factors. It explained that a pending appeal did not postpone debarment because the statute treats an entered judgment as a conviction. The notice also warns that knowing use of Shafa's services by a person with an approved or pending application can trigger civil monetary penalties. No later appeal outcome is asserted.
- Why it matters
- Drug-development and import screening must consider the applicable FDA debarment scope, which differs from healthcare-program exclusion screening.
- Response type
- Assess
- Confidence
- High
- Who this affects
- Health systems, Provider networks
- Jurisdiction
- Federal
- Agencies
- FDA
- Entities
- Rahim Shafa
- Action type
- Exclusion
- Event date
- Aug 31, 2026
- Alleged conduct
- Federal felony convictions relating to drug regulation and importation formed the basis of FDA's order.
- Resolution
- Permanent drug-application services debarment and 20-year import debarment; the controlled Exclusion category here denotes FDA debarment, not an OIG exclusion.
- First seen
- Sep 6, 2026
- Last materially changed
- Sep 6, 2026
- Why it is still here
- Retained for the organizational control review described in the recommended action, informed by the dated exclusion matter and its documented operational mechanism.
What to do nextCheck FDA debarment controls for relevant services and imports, including contractors serving drug applicants, and verify the order’s exact scope before engaging a screened person.
- Screen the relevant FDA debarment list as well as healthcare exclusion sources.
Permalink: #fda-rahim-shafa-debarment · Development ID GC-2026-0029
P3
CARRYOVER
Operationally relevant
Final
- What changed
Poul Thorsen pleaded guilty to wire fraud on September 1, 2026 after his extradition from Germany in May. DOJ's Northern District of Georgia release states that he diverted more than $1 million of CDC grant money. Sentencing was scheduled for December 1, which remained a future date as of the September 26 coverage cutoff; the release does not report an imposed sentence. The more than $11 million awarded to Danish agencies was the broader grant funding, not the amount identified as stolen.
Thorsen became principal investigator responsible for administering the grants in 2002. Between February 2004 and June 2008, he submitted over a dozen false reimbursement invoices bearing a forged CDC laboratory chief's signature. Aarhus University transferred money to accounts it believed belonged to the CDC, but the accounts were his personal accounts; the release also identifies diverted funds from Odense University Hospital. The mechanism highlights the importance of independently checking invoices, authorization and bank-account ownership across international research collaborations.
- Why it matters
- Investigator-supplied invoices and payment instructions need independent checks, particularly where collaborators believe a personal account belongs to a government agency.
- Response type
- Assess
- Confidence
- High
- Who this affects
- Health systems, Provider networks
- Jurisdiction
- Federal
- Agencies
- DOJ, HHS-OIG
- Entities
- Poul Thorsen
- Action type
- Criminal resolution
- Event date
- Sep 1, 2026
- Alleged conduct
- False invoices and forged authorization diverted research grants into personal accounts.
- Resolution
- Guilty plea entered; sentence has not been imposed. The $1 million describes diverted funds, not a fine.
- First seen
- Sep 6, 2026
- Last materially changed
- Sep 6, 2026
- Why it is still here
- Retained for the organizational control review described in the recommended action, informed by the dated criminal resolution matter and its documented operational mechanism.
What to do nextVerify payee-account ownership and invoice authorization independently of the investigator, separate research approval from payment release, and investigate unusual reimbursement instructions.
- Independently verify beneficiary bank accounts.
- Separate investigator approval from reimbursement release.
Permalink: #cdc-autism-research-grant-wire-fraud-plea · Development ID GC-2026-0036
P3
CARRYOVER
Operationally relevant
Final
- What changed
The U.S. Attorney's Office announced that Loretta Pyeatt pleaded guilty on September 4, 2026 to fraud in connection with access devices after stealing at least $321,000 from a care client. The release describes employment from roughly July 2023 through September 2025 and a client who received Social Security retirement and Veterans Affairs benefits. Sentencing was scheduled for December 9. That date was still future at the September 26 coverage cutoff, so the reported development is the guilty plea, not an imposed prison term.
The client gave Pyeatt debit cards to buy groceries, but she admitted using the access for cash withdrawals and other unauthorized purchases. Transactions increased from approximately 20 to 30 a month before her involvement to as many as 330 a month. The account had at least $232,026 when she began and less than $5,600 by July 2025. These details show how limited purchasing permission became repeated access to a vulnerable person's funds and incoming benefits. The release's maximum statutory penalty describes possible sentencing exposure only; it does not determine the sentence or establish that every transaction was independently adjudicated.
- Why it matters
- Client-fund safeguards need to distinguish authorized purchases from unrestricted withdrawal access and identify changes in transaction frequency or balances.
- Response type
- Assess
- Confidence
- High
- Who this affects
- Health systems, Provider networks
- Jurisdiction
- Federal
- Agencies
- DOJ
- Entities
- Loretta Pyeatt
- Action type
- Criminal resolution
- Event date
- Sep 4, 2026
- Alleged conduct
- Debit cards entrusted for groceries were used for unauthorized purchases and cash withdrawals.
- Resolution
- Guilty plea entered; no sentence or fine has yet been imposed.
- First seen
- Sep 6, 2026
- Last materially changed
- Sep 6, 2026
- Why it is still here
- Retained for the organizational control review described in the recommended action, informed by the dated criminal resolution matter and its documented operational mechanism.
What to do nextReview client-fund permissions, independent reconciliations, receipts and transaction alerts. Provide a complaint route outside the caregiver's control and escalate unexplained withdrawals or rapid balance declines.
- Limit financial access to documented authorized tasks.
- Escalate unexplained transaction spikes and reconcile receipts.
Permalink: #dent-county-caregiver-access-device-plea · Development ID GC-2026-0042
P3
CARRYOVER
Operationally relevant
Settled
- What changed
DOJ announced September 1, 2026 that Novum Pharmaceutical Research Services of Delaware, Inc. agreed to pay $3,345,000 to resolve False Claims Act allegations concerning a $2 million Second Draw Paycheck Protection Program loan. Novum received the loan and full forgiveness, but the government alleged that it was ineligible under the program's employee-based size standard. The settlement also resolves whistleblower claims. DOJ states that the resolved claims remain allegations, with no determination of liability; the announcement does not independently prove that the settlement payment was completed.
For the Second Draw program described in the release, eligibility required no more than 300 employees including domestic and foreign affiliates. Novum certified that it and its affiliates had fewer than 300, while DOJ says their combined workforce exceeded 300, including employees of its India-based ultimate parent, Lambda Therapeutic Research. The distinction is the applicant's consolidated eligibility calculation, rather than simply its own payroll. Although Novum is a research business, the case concerns SBA relief lending and forgiveness certifications, not reimbursement for healthcare services or a new Medicaid eligibility rule.
- Why it matters
- Relief-program certifications require the affiliate calculation specified by that program, including relevant foreign affiliates.
- Response type
- Assess
- Confidence
- High
- Who this affects
- Health systems, Provider networks
- Jurisdiction
- Federal
- Agencies
- DOJ
- Entities
- Novum Pharmaceutical Research Services of Delaware, Inc.
- Action type
- Settlement
- Event date
- Sep 1, 2026
- Alleged conduct
- Second Draw eligibility and forgiveness were allegedly obtained despite aggregate affiliate headcount exceeding the program threshold.
- Resolution
- Agreement to pay $3,345,000 resolving allegations involving a $2 million Second Draw PPP loan and forgiveness; no determination of liability.
- First seen
- Sep 6, 2026
- Last materially changed
- Sep 6, 2026
- Why it is still here
- Retained for the organizational control review described in the recommended action, informed by the dated settlement matter and its documented operational mechanism.
What to do nextRetain contemporaneous affiliate and workforce calculations supporting application and forgiveness certifications, and investigate unresolved discrepancies with finance and counsel.
- Include relevant domestic and foreign affiliates in eligibility analysis.
- Retain evidence supporting application and forgiveness certifications.
Permalink: #novum-ppp-affiliate-size-settlement · Development ID GC-2026-0044